Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?

Dermatology (Basel, Switzerland) - 1 Jan 2011

Mueller Simon M, Itin Peter, Haeusermann Peter

Abstract excerpt

Cryopyrin-associated periodic fever syndrome (CAPS) is a rare inherited disease due to mutations in the NLRP3 (also called CIAS1) gene on chromosome 1q44 resulting in overproduction of interleukin-1. CAPS comprises three clinically overlapping disorders including Muckle-Wells syndrome. We report on two half-siblings with Muckle-Wells syndrome who were successfully treated with the interleukin-1 beta antibody...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carrier Proteins

Share to Cryopyrin-Associated Periodic Syndromes

Share to Interleukin-1beta

Share to NLR Family, Pyrin Domain-Containing 3 Protein

Share to Recurrence

Share to Treatment Outcome

Source

Identifiers

PMID: 21967869
DOI: 10.1159/000331580

Genes

CAPS
NLRP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?PMID 21967869Read ↗

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.Semantic proximity Read ↗

Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.Semantic proximity Read ↗

Canakinumab for the treatment of cryopyrin-associated periodic syndromes.Semantic proximity Read ↗

Use of canakinumab in the cryopyrin-associated periodic syndrome.Semantic proximity Read ↗

Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.Semantic proximity Read ↗

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.Semantic proximity Read ↗

Cryopyrin-associated periodic syndromes: diagnosis and management.Semantic proximity Read ↗

Pharmacological treatment options for cryopyrin-associated periodic syndromes.Semantic proximity Read ↗

Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.Semantic proximity Read ↗

Diagnosis of cryopyrin-associated periodic syndrome: challenges, recommendations and emerging concepts.Semantic proximity Read ↗

Guidelines for the management and treatment of periodic fever syndromes: Cryopyrin-associated periodic syndromes (cryopyrinopathies - CAPS).Semantic proximity Read ↗

[CAPS: cryopyrin-associated periodic syndrome].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.